Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:50905
Name inflammatory myofibroblastic tumor
Definition A mesenchymal cell neoplasm that has_material_basis_in myofibroblastic cells admixed with inflammatory cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer mesenchymal cell neoplasm inflammatory myofibroblastic tumor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ALK fusion Crizotinib inflammatory myofibroblastic tumor sensitive detail...
EML4 - ALK Crizotinib inflammatory myofibroblastic tumor predicted - sensitive detail...
ALK rearrange Ceritinib inflammatory myofibroblastic tumor sensitive detail...
ALK rearrange Crizotinib inflammatory myofibroblastic tumor sensitive detail...
CD274 positive Pembrolizumab inflammatory myofibroblastic tumor predicted - sensitive detail...
ALK rearrange Brigatinib inflammatory myofibroblastic tumor sensitive detail...
ALK rearrange Lorlatinib inflammatory myofibroblastic tumor sensitive detail...
EML4 - ALK Alectinib inflammatory myofibroblastic tumor predicted - sensitive detail...
ALK rearrange Alectinib inflammatory myofibroblastic tumor sensitive detail...
ALK positive Alectinib inflammatory myofibroblastic tumor predicted - sensitive detail...
EML4 - ALK ALK I1171N Alectinib inflammatory myofibroblastic tumor predicted - resistant detail...
EML4 - ALK ALK I1171N Lorlatinib inflammatory myofibroblastic tumor predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT04925609 Phase Ib/II Brigatinib Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED) Recruiting NLD | FRA 0